Patents by Inventor Haruo Yoshii
Haruo Yoshii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6627194Abstract: Activated immunoglobulin which is useful as an eosinophilia-suppressing agent, immunomodulating agent, therapeutic agent for autoimmune diseases, anfiinflammatory agent and antiallergic agent is obtained by admixing immunoglobulin with a histamine component and then substantially or completely removing the histamine component. The histamine component may be removed or separated by dialysis, gel filtration, adsorption chromatography, ion exchange chromatography, or affinity chromatography. The method imparts pharmacological activity which is not inherently available in immunoglobulin of the natural type to immunoglobulin. The activated immunoglobulin of the present invention has an immunomodulating action which is clearly different from that of conventional immunosuppressive agents.Type: GrantFiled: August 8, 1996Date of Patent: September 30, 2003Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Mitsuru Naiki, Yuriko Fukata
-
Patent number: 6566386Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.Type: GrantFiled: April 23, 2001Date of Patent: May 20, 2003Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Yuriko Fukata
-
Patent number: 6440978Abstract: The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention relates to a therapeutic agent containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient: wherein R is hydrogen or a halogen. The therapeutic agent for dermatitis according to the present invention effectively and in a dose-dependent manner suppresses antigen-induced swelling in a mouse ear, a recognized animal model for atopic dermatitis, and suppresses the antigen-induced flare-up reaction in mice which occurred with the swelling reaction. In addition, no adverse reaction in the skin are observed.Type: GrantFiled: April 12, 2001Date of Patent: August 27, 2002Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Akihiro Fujita
-
Publication number: 20020004058Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.Type: ApplicationFiled: April 23, 2001Publication date: January 10, 2002Inventors: Haruo Yoshii, Yuriko Fukata
-
Publication number: 20010056097Abstract: The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents.Type: ApplicationFiled: April 12, 2001Publication date: December 27, 2001Inventors: Haruo Yoshii, Akihiro Fujita
-
Patent number: 6187803Abstract: A drug preparation for oral administration containing histamine-added immunoglobulin as an effective component may be used for prevention or treatment of allergic diseases such as bronchial asthma, allergic rhinitis, vasomotor rhinitis, urticaria, chronic eczema and atopic dermatitis; autoimmune diseases such as multiple sclerosis, chronic rheumatoid arthritis and systemic lupus erythematodes; various immunodeficiency syndromes; and also eosinophilia or various inflammatory diseases caused by infectious diseases, parasitic diseases, diseases of respiratory organs, autoimmune diseases, and malignant tumors. The drug preparation which can be administered orally can be taken by patients easier than an injectable preparation without loss of effectiveness. Therefore, the drug preparation for oral administration of the present invention is practical and highly useful.Type: GrantFiled: January 26, 1998Date of Patent: February 13, 2001Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Yuriko Yamazaki
-
Patent number: 5856113Abstract: Fragments of cell membrane of erythrocyte are used as an antigen for insolubilization in enzyme immunoassay to provide a highly sensitive, excellent quantitative method for measuring anti-erythrocyte antibody. The cell membrane fragments of erythrocyte are the residual membrane fraction after removal of soluble cytoplasm proteins which interfere with the absorbance analysis of enzyme-linked immunosorbent assay (ELISA). The cell membrane fragments of erythrocyte which are used as an antigen may be prepared by destroying the erythrocytes to obtain a cell membrane fragment fraction and a cytoplasm protein fraction. The two fractions may be separated or fractionated by gel filtration, ultrafiltration or centrifugation to isolate the cell membrane fragment fraction. A solution of the cell membrane fragments of erythrocyte is substantially transparent and is useful as an insolubilized antigen for ELISA. The antigen is shelf stable for extended periods when stored in a cool, dark location.Type: GrantFiled: July 31, 1996Date of Patent: January 5, 1999Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Yuriko Fukata
-
Patent number: 5780026Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.Type: GrantFiled: August 8, 1994Date of Patent: July 14, 1998Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Yuriko Fukata